IMPORTANT SAFETY INFORMATIONPRESCRIBING INFORMATION

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Stay up to date on FOLOTYN + Spectrum Pharmaceuticals

Sign up for updates to get news on FOLOTYN + Spectrum delivered to your inbox:

By signing up for updates I agree to receive emails from Spectrum Pharmaceuticals related to relapsed or refractory PTCL, FOLOTYN, other Spectrum products, and Spectrum corporate news and events.

Email address: (Required)

Information you submit will be used as described in our Privacy Policy >, and by using this feature you agree to adhere to our Terms of Use >.